Peter G. Smith
YOU?
Author Swipe
View article: The polarisation behaviour of OJ 287 viewed through radio, millimetre, and optical observations between 2015 and 2017
The polarisation behaviour of OJ 287 viewed through radio, millimetre, and optical observations between 2015 and 2017 Open
OJ 287 is a bright blazar with century-long observations, and one of the strongest candidates to host a supermassive black hole binary. Its polarisation behaviour between 2015 and 2017 (MJD 57300–58000) contains several interesting events …
View article: The polarisation behaviour of OJ 287 viewed through radio, millimetre and optical observations between 2015 and 2017
The polarisation behaviour of OJ 287 viewed through radio, millimetre and optical observations between 2015 and 2017 Open
OJ 287 is a bright blazar with century-long observations, and one of the strongest candidates to host a supermassive black hole binary. Its polarisation behaviour between 2015 and 2017 (MJD 57300-58000) contains several interesting events …
View article: Fractional Doses of Pneumococcal Conjugate Vaccine — A Noninferiority Trial
Fractional Doses of Pneumococcal Conjugate Vaccine — A Noninferiority Trial Open
In a three-dose schedule (two primary doses and a booster), 40% doses of PCV13 were noninferior to full doses for all included serotypes. Lower doses of PCV13 and PCV10 did not meet the criteria for noninferiority. (Funded by the Bill and …
View article: Immunogenicity and vaccine-serotype carriage prevalence after full or fractional doses of Pneumococcal Conjugate Vaccines in Kenyan infants: an individually randomised, controlled, non-inferiority trial
Immunogenicity and vaccine-serotype carriage prevalence after full or fractional doses of Pneumococcal Conjugate Vaccines in Kenyan infants: an individually randomised, controlled, non-inferiority trial Open
Background Pneumococcal conjugate vaccines (PCVs) are the most expensive component of the routine immunisation schedule in Gavi-supported countries. As countries transition out of Gavi support, PCV programmes are at risk. We assessed wheth…
View article: A biocatalytic platform for the synthesis of 2′-functionalized nucleoside analogues
A biocatalytic platform for the synthesis of 2′-functionalized nucleoside analogues Open
Nucleosides functionalized at the 2′-position play a crucial role in therapeutics, serving as both small molecule drugs and modifications in therapeutic oligonucleotides. However, the synthesis of these molecules often presents significant…
View article: Integrated management of HIV, diabetes, and hypertension in sub-Saharan Africa (INTE-AFRICA): a pragmatic cluster-randomised, controlled trial
Integrated management of HIV, diabetes, and hypertension in sub-Saharan Africa (INTE-AFRICA): a pragmatic cluster-randomised, controlled trial Open
European Union Horizon 2020 and Global Alliance for Chronic Diseases.
View article: Identification of pre-determined steroids in commercially available dietary and traditional supplement products in South Africa
Identification of pre-determined steroids in commercially available dietary and traditional supplement products in South Africa Open
Background An age-old fable can be traced as far back to third century BC that shows ‘sport supplements’ being used by athletes of that era, who made use of ‘substances’ , with the aim to improve performance. In more recent times, subseque…
View article: Identification of pre-determined steroids in commercially available dietary and traditional supplement products in South Africa
Identification of pre-determined steroids in commercially available dietary and traditional supplement products in South Africa Open
Background An age-old fable can be traced as far back to third century BC that shows ‘sport supplements’ being used by athletes of that era, who made use of ‘substances’ , with the aim to improve performance. In more recent times, subseque…
View article: Supplementary Figures 1-3, Table 1 from Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma
Supplementary Figures 1-3, Table 1 from Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma Open
PDF file - 116K
View article: Supplementary Figures 1-3, Table 1 from Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma
Supplementary Figures 1-3, Table 1 from Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma Open
PDF file - 116K
View article: Supplementary Figure 1 from Nedd8-Activating Enzyme Inhibitor MLN4924 Provides Synergy with Mitomycin C through Interactions with ATR, BRCA1/BRCA2, and Chromatin Dynamics Pathways
Supplementary Figure 1 from Nedd8-Activating Enzyme Inhibitor MLN4924 Provides Synergy with Mitomycin C through Interactions with ATR, BRCA1/BRCA2, and Chromatin Dynamics Pathways Open
PDF file - 1215KB, Full Length Western Blots.
View article: Data from Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma
Data from Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma Open
The NEDD8-activating enzyme is upstream of the 20S proteasome in the ubiquitin/proteasome pathway and catalyzes the first step in the neddylation pathway. NEDD8 modification of cullins is required for ubiquitination of cullin-ring ligases …
View article: Supplementary Figure 4 from Nedd8-Activating Enzyme Inhibitor MLN4924 Provides Synergy with Mitomycin C through Interactions with ATR, BRCA1/BRCA2, and Chromatin Dynamics Pathways
Supplementary Figure 4 from Nedd8-Activating Enzyme Inhibitor MLN4924 Provides Synergy with Mitomycin C through Interactions with ATR, BRCA1/BRCA2, and Chromatin Dynamics Pathways Open
PDF file - 145KB, Comparison of the Degree of Interaction between MLN4924 and 14 Different Agents as Measured by Nonlinear Blending Values.
View article: Supplementary Materials and Methods, Figure Legends from Nedd8-Activating Enzyme Inhibitor MLN4924 Provides Synergy with Mitomycin C through Interactions with ATR, BRCA1/BRCA2, and Chromatin Dynamics Pathways
Supplementary Materials and Methods, Figure Legends from Nedd8-Activating Enzyme Inhibitor MLN4924 Provides Synergy with Mitomycin C through Interactions with ATR, BRCA1/BRCA2, and Chromatin Dynamics Pathways Open
PDF file - 68KB
View article: Data from Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma
Data from Molecular and Cellular Effects of NEDD8-Activating Enzyme Inhibition in Myeloma Open
The NEDD8-activating enzyme is upstream of the 20S proteasome in the ubiquitin/proteasome pathway and catalyzes the first step in the neddylation pathway. NEDD8 modification of cullins is required for ubiquitination of cullin-ring ligases …
View article: Supplementary Figure S1 from H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma
Supplementary Figure S1 from H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma Open
H3B-6527 effects in a HCC cell line Hep3B orthotopic xenografts in female nude mice.
View article: Supplemental Figure 1 Part 1 from The NEDD8-Activating Enzyme Inhibitor MLN4924 Disrupts Nucleotide Metabolism and Augments the Efficacy of Cytarabine
Supplemental Figure 1 Part 1 from The NEDD8-Activating Enzyme Inhibitor MLN4924 Disrupts Nucleotide Metabolism and Augments the Efficacy of Cytarabine Open
Supplemental Figure 1 Part 1. Quantification of metabolomic data
View article: Supplementary Table 1 from Disrupting Protein NEDDylation with MLN4924 Is a Novel Strategy to Target Cisplatin Resistance in Ovarian Cancer
Supplementary Table 1 from Disrupting Protein NEDDylation with MLN4924 Is a Novel Strategy to Target Cisplatin Resistance in Ovarian Cancer Open
PDF file - 71K, Supplemental Table 1. Proteins Altered >2-fold by Treatment with MLN4924.
View article: Supplementary Figure 1 from Disrupting Protein NEDDylation with MLN4924 Is a Novel Strategy to Target Cisplatin Resistance in Ovarian Cancer
Supplementary Figure 1 from Disrupting Protein NEDDylation with MLN4924 Is a Novel Strategy to Target Cisplatin Resistance in Ovarian Cancer Open
PDF file - 1755K, Supplemental Figure 1: Effects of targeted p65 knockdown on cisplatin sensitivity.
View article: Supplementary Figure S2 from H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma
Supplementary Figure S2 from H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma Open
RNA-seq analysis of 24 CCLE HCC cell lines.
View article: Supplementary Figure S3andS4 from H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma
Supplementary Figure S3andS4 from H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma Open
H3B-6527 efficacy studies in 30 PDX models show that 10 models are responsive
View article: Supplemental Figure 3 from The NEDD8-Activating Enzyme Inhibitor MLN4924 Disrupts Nucleotide Metabolism and Augments the Efficacy of Cytarabine
Supplemental Figure 3 from The NEDD8-Activating Enzyme Inhibitor MLN4924 Disrupts Nucleotide Metabolism and Augments the Efficacy of Cytarabine Open
Supplemental Figure 3. Schematic of pyrimidine nucleotide metabolism pathway.
View article: Supplementary Figure 2 from Disrupting Protein NEDDylation with MLN4924 Is a Novel Strategy to Target Cisplatin Resistance in Ovarian Cancer
Supplementary Figure 2 from Disrupting Protein NEDDylation with MLN4924 Is a Novel Strategy to Target Cisplatin Resistance in Ovarian Cancer Open
PDF file - 3554K, Supplemental Figure 2: Effects of caspase inhibition and antioxidant treatment on MLN4924/cisplatin-induced DNA damage.
View article: Supplemental Figure 1 Part 2 from The NEDD8-Activating Enzyme Inhibitor MLN4924 Disrupts Nucleotide Metabolism and Augments the Efficacy of Cytarabine
Supplemental Figure 1 Part 2 from The NEDD8-Activating Enzyme Inhibitor MLN4924 Disrupts Nucleotide Metabolism and Augments the Efficacy of Cytarabine Open
Supplemental Figure 1 Part 2. Quantification of metabolomic data continued.
View article: Supplementary Table S2andS3 from H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma
Supplementary Table S2andS3 from H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma Open
H3B-6527 response in 40 HCC cell lines and 625 cell lines.
View article: Supplementary Figure S1 from H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma
Supplementary Figure S1 from H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma Open
H3B-6527 effects in a HCC cell line Hep3B orthotopic xenografts in female nude mice.
View article: Supplementary Figure 1 from Disrupting Protein NEDDylation with MLN4924 Is a Novel Strategy to Target Cisplatin Resistance in Ovarian Cancer
Supplementary Figure 1 from Disrupting Protein NEDDylation with MLN4924 Is a Novel Strategy to Target Cisplatin Resistance in Ovarian Cancer Open
PDF file - 1755K, Supplemental Figure 1: Effects of targeted p65 knockdown on cisplatin sensitivity.
View article: Supplementary Table 1 from Disrupting Protein NEDDylation with MLN4924 Is a Novel Strategy to Target Cisplatin Resistance in Ovarian Cancer
Supplementary Table 1 from Disrupting Protein NEDDylation with MLN4924 Is a Novel Strategy to Target Cisplatin Resistance in Ovarian Cancer Open
PDF file - 71K, Supplemental Table 1. Proteins Altered >2-fold by Treatment with MLN4924.
View article: Supplementary Figure S2 from H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma
Supplementary Figure S2 from H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma Open
RNA-seq analysis of 24 CCLE HCC cell lines.